Synapse - Radiation Oncology, Department of

Results (5288)

Proton radiotherapy for incurable recurrent or metastatic cancers of the head and neck by the RTOG 8502 hypofractionated palliative schedule

Meeting Abstract

Lok, B. H.; Zong, J.; Gutinov, S. I.; Cai, X.; Deselm, C.; Romesser, P. B.; Lanning, R. M.; Shcherba, M.; Xiao, H.; Sherman, E. J.; more...
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Comparison of outcomes following recurrence or metastasis in HPV plus and HPV-oropharyngeal carcinoma treated with definitive chemoradiation using IMRT

Meeting Abstract

Leeman, J. E.; Li, J. G.; Venigalla, P.; Zumsteg, Z. S.; McBride, S. M.; Boyle, J.; Roman, B. R.; Sherman, E. J.; Lee, N. Y.; Riaz, N.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Natural history following recurrence after definitive locoregional treatment in 1000+ cases of locally advanced head and neck squamous cell carcinoma

Meeting Abstract

Leeman, J. E.; Li, J. G.; Venigalla, P.; Zumsteg, Z. S.; McBride, S. M.; Boyle, J.; Roman, B. R.; Sherman, E. J.; Lee, N. Y.; Riaz, N.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

Event-free survival (EFS) and overall survival (OS) of MYCN-amplified stage 2/3 neuroblastoma with or without autologous stem-cell transplantation (ASCT)

Meeting Abstract

Kushner, B. H.; Modak, S.; LaQuaglia, M. P.; Wolden, S. L.; Basu, E. M.; Roberts, S. S.; Kramer, K.; Cheung, I. Y.; Cheung, N. K. V.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

HPV cell free DNA as a marker of response to chemoradiation for HPV-positive oropharngeal cancers

Meeting Abstract

Higginson, D. S.; Damerla, R.; Scher, E. D.; Gutinov, S. I.; Thompson, C.; Cleary, C.; McBride, S. M.; Sherman, E. J.; Riaz, N.; Lee, N.
Journal of Clinical Oncology (2016)

Fulltext@MSK | Save

18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG)